Skip to main content

Market Overview

Renalytix AI Stock Jumps After 10-Year US Government Contract For Kidney Disease Testing Services

Share:
Renalytix AI Stock Jumps After 10-Year US Government Contract For Kidney Disease Testing Services
  • Renalytix AI plc (NASDAQ: RNLX) stock is rising on the heels of a 10-year contract from the United States Government to provide KidneyIntelX early-stage kidney disease bioprognostic testing services.
  • The contract, offered through the General Services Administration, covers laboratory testing services that can be provided through more than 140 U.S. government departments, agencies.
  • The contract is effective as of April 15 and has a five-year term with a five-year extension option.
  • Under the contract, KidneyIntelX pricing is set at $950 per reportable result.
  • Individual physicians operating within government-sponsored healthcare programs can now order KidneyIntelX testing for their patients with diabetic kidney disease.
  • Price Action: RNLX shares are up 21.7% at $30.7 in the premarket session on the last check Thursday.
 

Related Articles (RNLX)

View Comments and Join the Discussion!

Posted-In: BriefsBiotech Government News Health Care Contracts Small Cap General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com